Fierce Pharma April 26, 2024
For the second time in four years, AbbVie’s Rinvoq (upadacitinib) has shown superior efficacy to Regeneron and Sanofi’s powerhouse Dupixent (dupilumab) in a head-to-head study in patients with atopic dermatitis (AD).
In the LEVEL UP trial testing patients age 12 and older with moderate-to-severe AD who had an inadequate response to systemic therapy, 20% of those on Rinvoq achieved nearly complete skin clearance with little or no itch after 16 weeks, compared to 9% of those on Dupixent. AbbVie’s anti-inflammatory treatment also conquered Dupixent in all secondary objectives of the phase 3b/4 study.
For the primary endpoint, the standard of comparison was determining the number of patients who achieved a 90% or greater reduction on the Eczema Area and Severity...
Today's Sponsors
Today's Sponsor